Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
210.01
+3.47 (1.68%)
At close: Dec 11, 2025, 4:00 PM EST
210.46
+0.45 (0.21%)
After-hours: Dec 11, 2025, 7:59 PM EST
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.99B in the quarter ending September 28, 2025, with 6.77% growth. This brings the company's revenue in the last twelve months to $92.15B, up 5.08% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$92.15B
Revenue Growth
+5.08%
P/S Ratio
5.49
Revenue / Employee
$667,263
Employees
138,100
Market Cap
505.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 28, 2014 | 74.33B | - | - |
| Dec 29, 2013 | - | - | - |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | -7.77B | -12.72% |
| Jan 1, 2006 | 61.10B | 7.77B | 14.57% |
| Jan 2, 2005 | 53.32B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
JNJ News
- 5 hours ago - Johnson & Johnson: Reliable Cash Flows, Moderate Expectations - Seeking Alpha
- 2 days ago - GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities - Seeking Alpha
- 2 days ago - 5 defensive stocks traders are buying before the Fed rate-cut decision - Invezz
- 2 days ago - 1 Major Factor Behind the Healthcare Sector's Recent Surge - The Motley Fool
- 2 days ago - Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma - PRNewsWire
- 3 days ago - Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 days ago - Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma - PRNewsWire
- 6 days ago - Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC - PRNewsWire